Fat Science

Ever hear someone say GLP-1 medications cause osteoporosis or make your hair fall out?
This episode tackles the top 10 biggest myths about GLP-1 medications flooding social media and separates the science from the scary headlines. Dr. Cooper breaks down what's actually happening in your body versus what the internet claims, from bone density concerns to the dreaded "Ozempic face."
KEY TAKEAWAYS
·  GLP-1 medications don't cause osteoporosis - inadequate nutrition while losing weight can weaken bones
·  Hair loss is typically from nutritional deficits, not the medication itself
·  These drugs slow gastric emptying but don't cause permanent stomach paralysis
·  Weight regain after stopping is expected since you're treating a chronic medical condition
·  Muscle loss comes from eating too little, not from the medication directly
·  The thyroid cancer warning comes from rodent studies and hasn't been observed in humans
·  GLP-1s actually protect the pancreas rather than damage it
NOTABLE QUOTE
"Metabolic dysfunction is biological, it's not something within your means to correct just through lifestyle strategies." — Dr. Emily Cooper
Links & Resources
Podcast Home: fatsciencepodcast.com
Cooper Center for Metabolism: coopermetabolic.com
Resources from Dr. Cooper: coopermetabolic.com/resources
Join Our Community: patreon.com/cw/FatSciencePodcast
Submit Your Question: [email protected] or [email protected]
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

The obesity medication landscape just changed — again. One brand-new pill is already in pharmacies, and five more are in various stages of approval. But the real story isn't the drugs themselves: it's what they're revealing about how your metabolism actually works, and why willpower was never the problem.
This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down six metabolic medications — two newly FDA-approved and four in the pipeline — covering everything from a flexible new oral GLP-1 pill to drugs that target the brain's central metabolic pathway directly. Dr. Cooper explains the science behind each one, who might benefit, and what the pipeline tells us about the future of metabolic care. This is the most comprehensive drug update the show has done, and it arrives at a moment when the field is moving faster than ever.
Key Takeaways
Foundayo (orforglipron), approved April 1st, is the first small molecule oral GLP-1 — no empty stomach requirement, no cold chain, and potentially lower production costs long-term.

The amylin hormone may uniquely address both "I'm nourished" and "I weigh enough" signals in the brain — making the amylin pathway a powerful and underutilized target.

Retatrutide (Lilly's triple agonist targeting GLP-1, GIP, and glucagon receptors) is showing unprecedented effectiveness plus significant non-scale benefits, including fatty liver reduction — but is still years from approval.

The brain's melanocortin 4 receptor is the CEO of metabolism — regulating energy expenditure, appetite, and insulin — and new drugs targeting it represent the deepest intervention yet.

Many of these medications are showing weight-independent benefits, including improvements in kidney, liver, cardiovascular risk, sleep apnea, and joint health that have nothing to do with how much weight is lost.

Notable Quote
"Everybody focuses on appetite, and you just need to eat less. But now with these medications and how they actually affect our biology, it becomes very clear that there's so much more to this." — Dr. Emily Cooper
Links & Resources
Podcast Home: fatsciencepodcast.com
Cooper Center for Metabolism: coopermetabolic.com
Resources from Dr. Cooper: coopermetabolic.com/resources
Join Our Community: patreon.com/cw/FatSciencePodcast
Submit Your Question: [email protected] or [email protected]
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you been told insulin resistance testing doesn't exist or wondered if you're increasing your GLP-1 dose too quickly?
Dr. Cooper, Andrea, and Mark tackle listener questions from around the world, addressing common concerns about insulin resistance testing availability, managing severe GI side effects from higher doses, interpreting DEXA scan results, and developing sustainable maintenance strategies. They discuss the difference between hunger and food noise, explain why winter illness might stall weight loss, and share insights about visceral fat concerns even at normal weight.
KEY TAKEAWAYS
Insulin resistance can be tested through fasting insulin and glucose ratios, even in countries where insulin testing is less common

Rapid weight loss rates above 15% annually may indicate no need for dose increases

Severe GI side effects warrant investigation beyond medication adjustment, including gallbladder evaluation

DEXA scans provide valuable visceral fat measurements, but results should be interpreted alongside overall health markers

Maintenance strategies should focus on nutritional stability before considering medication tapering

NOTABLE QUOTE
"It's not that the medicine causes the rebound weight gain, it's that with the medication in there, the body is getting better signals, and then you go and take the medication away and you're in the same boat." — Dr. Emily Cooper
Links & Resources
Podcast Home: fatsciencepodcast.com
Cooper Center for Metabolism: coopermetabolic.com
Resources from Dr. Cooper: coopermetabolic.com/resources
Join Our Community: patreon.com/cw/FatSciencePodcast
Submit Your Question: [email protected] or [email protected]
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Are you getting a GLP-1 prescription from someone who's never examined you?
Dr. Vin Gupta, pulmonologist and former Chief Medical Officer at Amazon, joins Dr. Cooper to expose the dangerous gap between legitimate obesity medicine and the unregulated direct-to-consumer market. This conversation reveals why proper medical evaluation matters and how profit-driven platforms are exploiting desperate patients.
KEY TAKEAWAYS
GLP-1 medications require individualized medical evaluation, not one-size-fits-all prescribing
Direct-to-consumer microdosing platforms lack FDA approval and proper medical oversight
The erosion of trust in healthcare has created opportunities for unregulated treatments
Comprehensive metabolic care includes regular lab work, body composition monitoring, and personalized treatment plans
Technology should enhance medical care, not replace proper physician evaluation
NOTABLE QUOTE
"I see so many people that come in, you know, they're obsessed with monitoring their HRV, their heart rate variability, and yet they had no idea they have pre-diabetes and they had no idea that they have triglyceride levels through the roof." — Dr. Emily Cooper
GUEST BIO
Dr. Vin Gupta is a pulmonologist, public health expert, and medical analyst for NBC News. He served as Chief Medical Officer at Amazon and has dedicated his career to translating complex science into actionable health insights at both individual and population levels.
GLOSSARY
GLP-1 medications: Glucagon-like peptide-1 receptor agonists, medications that help regulate blood sugar and appetite, including brand names like Ozempic, Wegovy, and Zepbound
Microdosing: Taking smaller amounts of medication than officially prescribed or approved
Direct-to-consumer (D2C): Healthcare services that bypass traditional medical settings, often delivered through apps or online platforms
HRV: Heart rate variability, a measurement of the variation in time between heartbeats
Pre-diabetes: Blood sugar levels that are higher than normal but not high enough to be diagnosed as type 2 diabetes
Links & Resources
Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: [email protected] or [email protected]

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

What really happens when you stop GLP-1 medications — and are the headlines telling you the whole story? The answer is more nuanced than social media wants you to believe.
This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down four recent studies on GLP-1 treatment outcomes, weight regain, and a groundbreaking new drug that could preserve lean mass during treatment. They walk through the methodology behind each paper, explain why two studies asking the same question got opposite answers, and reveal what a new monoclonal antibody called bimagrumab could mean for the future of metabolic treatment.
Key Takeaways
When you stop treating any chronic metabolic condition, the condition returns — that's not failure, that's biology.

Real-world data showed 56% of people who stopped filling GLP-1 prescriptions maintained or continued losing weight — likely because they continued working with their clinician on alternative treatments.

A new monoclonal antibody called bimagrumab showed 11% body weight reduction on its own, while simultaneously increasing lean mass by 3% — without affecting appetite.

When combined with semaglutide, bimagrumab reduced lean mass loss from 28% to just 11% of total weight lost.

Not eating enough while on GLP-1s drives greater lean mass loss — nutrition is still the best tool for preserving muscle.

Notable Quote
"It wasn't my failure and it was disease underneath everything. Finding that out — that it wasn't my fault — that was the miracle of the whole process to me." — Andrea Taylor
Links & Resources
Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: [email protected] or [email protected]

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations